Develop

Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy

Shots: Spark to get exclusive, WW license to develop, manufacture and commercialize CG01 whereas CombiGene will continue to execute aspects of the preclinical program The companies will work together and will leverage their knowledge to address unmet needs for people living with drug-resistant focal epilepsy CG01 is an investigational gene therapy that aims to treat …

Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy Read More »

Orion Signs a License and Research Agreement with Alligator to Develop Bispecific Antibody for the Treatment of Cancer

Shots: Alligator to receive up front & research support payments. If Orion exercises its options to continue the development and commercialization of the product then Alligator will be further eligible to receive $548.41M as development, approval, and sales milestone for all three product candidates along with royalties The focus of the collaboration is to discover …

Orion Signs a License and Research Agreement with Alligator to Develop Bispecific Antibody for the Treatment of Cancer Read More »

Exelixis Expands its Collaboration with Invenra to Develop Novel Biologics in Oncology

Shots: Invenra to receive $15.0M up front along with additional fees and funding to elect up to 20 additional targets in oncology & is eligible for development, regulatory, and commercial milestones along with royalties on net sales of any approved products Exelixis will own all Ab sequences discovered from the collaboration for uses in oncology …

Exelixis Expands its Collaboration with Invenra to Develop Novel Biologics in Oncology Read More »

AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity

Shots: The companies collaborated to research, develop & commercialize small molecules directed against the GPR75 target with the potential to treat obesity and related co-morbidities The collaboration builds on the findings from the Regeneron Genetics Center of rare genetic mutations in the GPR75 gene associated with protection against obesity and on early joint research initiated …

AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity Read More »

Skyhawk Collaborate with Aragen to Develop Novel Small Molecule Therapeutics to Correct RNA Expression

Shots: Skyhawk collaborated with Aragen for the development of small molecule therapeutics that correct RNA expression Under the collaboration, Skyhawk will get multiple discovery chemistry and biology service solutions from Aragen The alliance focuses to accelerate Skyhawk’s research pipeline. Aragen’s research expertise will help Skyhawk to advance the development of its novel small molecule therapeutics …

Skyhawk Collaborate with Aragen to Develop Novel Small Molecule Therapeutics to Correct RNA Expression Read More »

Orchard Collaborates with Pharming to Develop and Commercialize OTL-105 for Hereditary Angioedema

Shots: Orchard to receive $17.5M up front including $10M in cash & $7.5M as equity investment at a premium to Orchard’s share and is also eligible to receive ~$189.5M as other milestones along with royalties on WW sales Pharming has granted WW rights to OTL-105 (ex vivo HSC gene therapy) & will be responsible for …

Orchard Collaborates with Pharming to Develop and Commercialize OTL-105 for Hereditary Angioedema Read More »

Kite Enter into a Partnership with Shoreline Biosciences to Develop Novel Allogeneic Cell Therapies

Shots: Shoreline is eligible to receive ~$2.3B including upfront, development and commercialization milestones and additional payments along with royalties. The agreement follows Kite’s investment in Shoreline’s recent Series A financing The collaboration will utilize Shoreline’s iPSC differentiation and genetic reprogramming with Kite’s cell therapy to develop novel allogeneic therapies for hematologic malignancies Initially, the collaboration …

Kite Enter into a Partnership with Shoreline Biosciences to Develop Novel Allogeneic Cell Therapies Read More »

GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer

Shots: iTeos to receive $625M up front & is eligible to receive up to ~$1.45B in milestone upon achievement of certain milestones & royalties on ex-US sales. Both companies will share global development costs of EOS-448 and co-commercialize & share profits in the US GSK to receive an exclusive license for commercialization (Ex-US) & access …

GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer Read More »

Verona Pharma Signs $219M Agreement with Nuance Pharma to Develop and Commercialize Ensifentrine in Greater China

Shots: Verona Pharma to receive $40M including $25M upfront cash and $15M equity interest in Nuance Biotech, and is eligible to receive ~$179M in milestones along with royalties on net sales in Greater China (mainland China, Taiwan, Hong Kong and Macau) Verona Pharma granted Nuance Pharma exclusive right to develop & commercialize ensifentrine in Greater …

Verona Pharma Signs $219M Agreement with Nuance Pharma to Develop and Commercialize Ensifentrine in Greater China Read More »

BeiGene Signs an Exclusive Worldwide Collaboration with Shoreline to Develop and Commercialize Genetically Modified NK Cell Therapies

Shots: Shoreline to receive $45M up front in cash and is eligible to receive R&D funding, milestones along with royalties, following the achievement of certain milestones The companies will jointly develop cell therapies for four targets, with an option to further expand the collaboration. BeiGene will lead the clinical development globally while Shoreline will be …

BeiGene Signs an Exclusive Worldwide Collaboration with Shoreline to Develop and Commercialize Genetically Modified NK Cell Therapies Read More »

Amgen and Kyowa Kirin Collaborate to Develop and Commercialize KHK4083 for Atopic Dermatitis

Shots: Kyowa Kirin to receive ~$400M up front and an additional ~$850M as milestones along with royalties on future global sales. Both companies will share global development costs (Ex- Japan & the US) Amgen will responsible for the development, manufacturing, and commercialization of KHK4083 for all markets globally (Ex-Japan, where Kyowa Kirin will retain all …

Amgen and Kyowa Kirin Collaborate to Develop and Commercialize KHK4083 for Atopic Dermatitis Read More »

Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China

Shots: Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China SciNeuro to get an exclusive license to develop and commercialize alpha-synuclein targeted therapies in Greater China includes mainland China, Hong Kong, Macau, And Taiwan Alpha-synuclein directed therapies help to …

Eli Lilly Signs an Exclusive License Agreement with SciNeuro to Develop and Commercialize Alpha-synuclein Targeted Therapies in China Read More »

PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop Biosimilar Pembrolizumab

Shots: The agreement facilitates PlantForm’s collaborations in Brazil to provide affordable, effective cancer drugs to millions of Brazilians The 3yrs. research and development collaboration will culminate in protocols for P-I and P-III clinical trials. The companies will take biosimilar pembrolizumab to world markets, following the completion of clinical trials in Brazil Pembrolizumab is a biosimilar …

PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop Biosimilar Pembrolizumab Read More »

Ultragenyx Collaborates with n-Lorem Foundation to Advance Personalized Medicines Treatment for Patients with Ultra-Rare Diseases

Shots: The companies collaborated to develop the personalized medicines for patients with ultra-rare diseases. The collaboration involves additional resources, financial contribution, and experience from both the company The alliance strengthens n-Lorem’s mission to bring immediate hope and rapid treatment to ultra-rare disease patients in need n-Lorem Foundation provides a free and lifetime supply of ASO …

Ultragenyx Collaborates with n-Lorem Foundation to Advance Personalized Medicines Treatment for Patients with Ultra-Rare Diseases Read More »

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

Shots: AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration The expanded collaboration will utilize AbCellera’s technology stack, which includes Trianni Mouse and OrthoMab protein engineering platform AbCellera will generate panels of Abs against up to 8 new targets across multiple indications, selected by Gilead …

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications Read More »

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases

Shots: Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under the collaboration Takeda gets an exclusive right to develop and commercialize the mRNA transational modulators and has a time limited option to expands the collaboration for three additional targets for …

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases Read More »

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases

Shots: Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under the collaboration Takeda gets an exclusive right to develop and commercialize the mRNA transational modulators and has a time limited option to expands the collaboration for three additional targets for …

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases Read More »

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales of ADCs Pyxis gets a WW license to develop and commercialize PYX-201 and PYX-203. Pfizer will continue to support the development and advancement of ADCs portfolio via an equity investment …

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates Read More »

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates

Shots: Pfizer to receive an up front, equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales of ADCs Pyxis gets a WW license to develop and commercialize PYX-201 and PYX-203. Pfizer will continue to support the development and advancement of ADCs portfolio via an equity investment …

Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates Read More »

Takeda Signs a License Agreement with Genevant to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis

Shots: Genevant to receive up to $600M up front and milestone as well as royalties on future product sales Takeda get exclusive rights to access Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets The companies collaborated to discover, develop and commercialize the LNP-delivered nucleic acid therapeutics directed to previously inaccessible …

Takeda Signs a License Agreement with Genevant to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis Read More »

SMA Foundation Collaborates with PTC to Discover and Develop Regenerative Medicine

Shots: SMA Foundation and PTC will provide an initial investment of up to $60M in research to discover & develop regenerative treatments in neuromuscular diseases The focus of the agreement is advance scientific research in SMA and other neuromuscular disorders to develop new treatments The availability of several disease-modifying therapies has made regenerative interventions the …

SMA Foundation Collaborates with PTC to Discover and Develop Regenerative Medicine Read More »

Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes

Shots: Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future Additionally, Biolojic is eligible to receive royalties on sales of therapies that emerges during the collaboration The collaboration will leverage Biolojic’s AI-based multibody platform to discover and develop a potential novel Ab-based …

Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes Read More »

Qiagen Expand its Collaboration with Inovio to Develop Liquid Biopsy Based CDx for VGX-3100 to Treat Advanced Cervical Dysplasia

Shots: The companies collaborated to develop liquid biopsy-based CDx based on NGS technology to complement Inovio’s therapies. The collaboration initially focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from VGX-3100 QIAGEN’s bioinformatic expertise will raise the predictive biomarker power in Inovio’s patient selection. The assay will …

Qiagen Expand its Collaboration with Inovio to Develop Liquid Biopsy Based CDx for VGX-3100 to Treat Advanced Cervical Dysplasia Read More »

Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids

Shots: The companies collaborated to develop improved tissue-selective AAV vectors to realize effective gene therapy treatments for multiple life-threatening disorders The focus of this agreement is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency The collaboration comes two years after Sirion signed …

Sanofi Collaborates with Sirion to Develop Gene Therapy Treatment with Improved AAV Capsids Read More »

Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies

Shots: The companies signed a license agreement to deploy TcBuster for the manufacturing of gene-modified cell therapies Luminary gets a non-exclusive license for TcBuster and will use it in the LMY-920 program. Luminary plans to file an IND with the FDA in late 2021 The license agreement will allow Bio-Techne to increase its presence in …

Bio-Techne Collaborates with Luminary to Utilize TcBuster in the Development of CAR-T cell Therapies Read More »

Novartis Collaborates with Bill & Melinda Gates Foundation to Discover and Develop Gene Therapy for Sickle Cell Disease

Shots: The Gates Foundation will provide funding support to discover and develop in vivo gene therapy for SCD. The alliance brings together Novartis drug discovery and gene therapy expertise with Gates’ funding’s The focus of the agreement to address the disparity in access to treatments and to prioritize populations and regions bearing the greatest burden …

Novartis Collaborates with Bill & Melinda Gates Foundation to Discover and Develop Gene Therapy for Sickle Cell Disease Read More »

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory and sales milestone along with royalties on future sales MTEM will be responsible for research activities to discover next generation ETBs for multiple targets, of which BMS selected the first target. BMS to get an option to obtain …

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer Read More »

CureVac Collaborate with UK Government to Develop Vaccines Against SARS-CoV-2 variants

Shots: The collaboration combines expertise, resources and technology from both parties to develop and manufacture variant vaccines against SARS-CoV-2 variants. CureVac is expected to supply 50M doses of variant vaccines to the UK, following the regulatory approval The VTF and the CureVac will deploy mRNA platform to assess multiple SARS-CoV-2 variants and are expected to …

CureVac Collaborate with UK Government to Develop Vaccines Against SARS-CoV-2 variants Read More »

GSK Collaborate with CureVac to Develop Next Generation mRNA COVID-19 Vaccines

Shots: CureVac to receive $90.14M up front, $90.14M as milestones on the achievement of specific milestones. GSK will be the marketing authorization holder for the vaccine (Ex-Switzerland) and will have exclusive rights in all countries except Germany, Austria and Switzerland Additionally, GSK will support the manufacture of ~100M doses of CureVac’s first generation COVID-19 vaccine …

GSK Collaborate with CureVac to Develop Next Generation mRNA COVID-19 Vaccines Read More »

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development

Shots: CQC collaborates with Roche to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development The collaboration will employ CQC’s quantum chemistry platform ‘EUMEN’, to augment the Roche’s AD research efforts The multi-year collaboration will combine the expertise of both CQC and Roche to advance the application of quantum computing to pharmaceutical …

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development Read More »

Merck Signs an Exclusive Worldwide License Agreement with Artiva to Develop CAR-NK Cell Therapies

Shots: Artiva to receive $30M up front for the first 2 programs & an additional $15M, if Merck exercises its option for a third program. Artiva to get ~$612M/ program as development & commercial milestones and royalties on the global sales of the product emerge from the collaboration Artiva receives funding from Merck for each …

Merck Signs an Exclusive Worldwide License Agreement with Artiva to Develop CAR-NK Cell Therapies Read More »

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens

Shots: Cardiff University will receive milestone payments that advance from the discovery collaboration into clinical development and royalty payments on sales of any products that reach the market. Ervaxx will fund this program Ervaxx gains an exclusive license to Cardiff University patents claiming T cells and TCRs reactive to cancer-specific antigens and has the right …

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens Read More »

Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies

Shots: Tyris to receive up front, research milestone along with research funding and will be responsible for generating clinical lead candidates and will further progress them to clinical development Almirall to get an exclusive option to acquire gene therapies and progress them through clinical development to commercialization The collaboration will integrate Tyris’s non-viral based gene …

Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies Read More »

Genentech Signs ~$1B Pact with Ribometrix to Develop RNA-Targeted Small Molecule Therapies

Shots: Ribometrix to receive $25M up front, ~$1B+ as milestones along with royalties on sales of therapies emerges from the collaboration The companies collaborated on the discovery & preclinical development of programs. Genentech will lead further development and commercialization and will have exclusive rights to several predefined targets including an exclusive global license for the …

Genentech Signs ~$1B Pact with Ribometrix to Develop RNA-Targeted Small Molecule Therapies Read More »

Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy

Shots: Dewpoint to receive up front payment and up to $239M as research, development & commercial milestones along with royalties on sales of the therapies The companies collaborated for the development of therapies to treat DM1 The companies will collaborate their expertise to advance the novel therapeutic solutions addressing the patients’ needs Click here ­to­ read …

Pfizer Collaborates with Dewpoint to Develop Therapies for Rare Form of Muscular Dystrophy Read More »

Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China

Shots: Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions Both the companies …

Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China Read More »

Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases

Shots: Skyhawk to receive $40M as upfront and is eligible to receive up to $2.2B as milestones along with royalties on sales. Vertex to get an option to exclusively license WW IP rights to candidates discovered and developed under the collaboration directed at serious diseases Following the exercise of its options, Vertex will be responsible …

Skyhawk Collaborates with Vertex to Discover and Develop Novel Small Molecules Modulating RNA Splicing for Serious Diseases Read More »

Myovant Signs Agreement with Pfizer to Develop and Commercialize Relugolix in Oncology and Women’s Health

Shots: Myovant & Pfizer will jointly develop & commercialize ORGOVYX (relugolix) in advanced prostate cancer & if approved, relugolix combination tablet in women’s health in the US & Canada. Myovant will receive ~$4.2B including $650M upfront, $200M in regulatory milestones for FDA approvals for relugolix combination tablet in women’s health, and tiered sales milestones upon …

Myovant Signs Agreement with Pfizer to Develop and Commercialize Relugolix in Oncology and Women’s Health Read More »

Aurobindo Pharma Sign Agreement with COVAXX to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF

Shots: In the agreement, Aurobindo has obtained the exclusive rights to develop, manufacture & sell COVAXX’s UB-612 vaccine in India & UNICEF & also non-exclusive rights in other selected emerging & developing markets UB-612 is presently being assessed in P-I will be manufactured by Aurobindo in its Hyderabad facility has a manufacturing capacity of 220M …

Aurobindo Pharma Sign Agreement with COVAXX to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF Read More »

Merck Signs a ~$1B Pact with Janux to Develop Cancer Therapies Using T Cell Engager Technology

Shots: Janux to receive up to $500.5M/ target as upfront and milestones along with royalties on sales of product emerges from the collaboration, making a total deal value ~$1B. Merck will fund R&D performed under the agreement Merck to get an exclusive WW license to products & IP developed from the collaboration The focus of …

Merck Signs a ~$1B Pact with Janux to Develop Cancer Therapies Using T Cell Engager Technology Read More »

GSK Signs an Exclusive License Agreement with Surface Oncology to Develop and Commercialize SRF813

Shots: Surface Oncology to receive ~$85 M upfront and ~$730 M as milestones along with royalties on net sales of SRF813 GSK to get an exclusive right to develop and commercialize Surface Oncology’s preclinical program, SRF813 SRF813 is an IgG1 Ab targeting PVRIG (also k/a CD112), currently in IND-enabling studies with anticipated IND submission in …

GSK Signs an Exclusive License Agreement with Surface Oncology to Develop and Commercialize SRF813 Read More »

Genentech Signs a Worldwide License Agreement with Relay Therapeutics to Develop and Commercialize RLY-1971

Shots: Relay to receive $75M as upfront, $25M in additional near-term payments, and has the right to opt for 50/50 profit/cost-sharing on RLY-1971 in the US. If Relay exercises the option, it will be eligible to receive 50% profits on US sales & ~$410M as commercialization milestones & royalties on ex-US sales If Relay elects …

Genentech Signs a Worldwide License Agreement with Relay Therapeutics to Develop and Commercialize RLY-1971 Read More »

AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

Shots: Frontier to receive ~$100M including $55M upfront and remaining as milestones within the first 12mos. of collaboration and is eligible for development & commercial milestone that could exceed $1B, along with royalties on commercialized products Following the completion of pre-clinical development, AbbVie will lead global development and commercialization activities and costs for the programs …

AbbVie Collaborates with Frontier Medicines to Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets Read More »

PostEra Collaborates with NeuroLucent to Identify Therapies for Alzheimer’s Disease

Shots: NeuroLucent will receive an upfront along with additional payments upon the achievement of milestones. The companies collaborated to accelerate search for a therapeutic candidate PostEra will use its ML technology to optimize NeuroLucent’s lead compounds through a series of design make test cycles that has previously been shown to accelerate medicinal chemistry campaigns PostEra …

PostEra Collaborates with NeuroLucent to Identify Therapies for Alzheimer’s Disease Read More »

Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas

Shots: Schrödinger to receive $55M upfront and is eligible to receive $2.7B as preclinical, development, regulatory & commercial milestones along with royalties on sales of each product commercialized by BMS Schrödinger to grant BMS exclusive WW rights to develop & commercialize the development candidates emerges from the collaboration The collaboration will merge Schrödinger’s computational platform …

Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas Read More »

Novartis Signs a License Agreement with Mesoblast to Develop and Commercialize Remestemcel-L for ARDS

Shots: Mesoblast to receive $25M up front and $25M as equity investment with additional payments and royalties on achievement of development, regulatory and commercial milestones Novartis to acquire the exclusive WW rights to develop, commercialize & manufacture remestemcel-L for ARDS & access to a cell-therapy based platform with WW rights to a range of potential …

Novartis Signs a License Agreement with Mesoblast to Develop and Commercialize Remestemcel-L for ARDS Read More »

Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases

Shots: Lead Pharma receives ~$11.86M upfront and is eligible to receive funding and ~$307.9 as research, development, regulatory and commercial milestones along with royalties on sales of small molecules The companies will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for the development and global …

Roche Signs a License Agreement with Lead Pharma to Develop Oral Therapies for Immune-Mediated Diseases Read More »

AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer

Shots: Fusion to receive up front, as well as development milestones and other payments. The companies will jointly discover, develop, and have an option to co-commercialize novel TATs in the US while AstraZeneca will lead commercialization in the ROW with equal profit & loss sharing globally The collaboration leverages Fusion’s TAT platform and expertise in …

AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer Read More »

BMS Signs a Five-Year Agreement with Insitro to Develop Therapies for ALS and Frontotemporal Dementia

Shots: Insitro to receive $50M as up front, $20M as near-term operational milestones and is eligible to receive ~$2B+ as discovery, development, regulatory and commercial milestones along with royalties on sales of the therapies BMS will lead the clinical development, regulatory submissions, and commercialization activities. Insitro will apply its insitro Human (ISH) platform, to create …

BMS Signs a Five-Year Agreement with Insitro to Develop Therapies for ALS and Frontotemporal Dementia Read More »

Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19

Shots: Molecular Partners to receive $65.8M as up front, including equity, and will receive $164.7M as an option payment for both MP0420 and MP0423 along with royalties on sales of therapies. Novartis to get an option to in-license global rights of MP0420 and MP0423 During the option period, Molecular Partners will conduct a P-I study …

Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19 Read More »

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Shots: The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US The therapy is currently being evaluated in P-II study for …

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19 Read More »

Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

Shots: The companies collaborate for fast-track development of DNP-019 against COVID-19 The collaboration will expand Samsung’s CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing Samsung has introduced its proprietary cell-line technology, S-CHOice, demonstrating improved titers up to two-fold and maintaining …

Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19 Read More »

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China

Shots: ImmunoGen to receive $40M up front, ~$265M as development, regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain all rights to mirvetuximab in the US & ROW The collaboration accelerates the development path for mirvetuximab in Greater China and expands Huadong’s oncology portfolio …

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China Read More »

Henlius Signs a License Agreement with Essex to Co-develop HLX04 (biosimilar, bevacizumab) for Ophthalmic Diseases

Shots: Henlius to receive upfront, regulatory, and commercial milestone payments of ~$43M, eligible to receive $30M for every $1B above the first $600M of the cumulative net sales along with 10% royalties on net sales of the therapy Henlius will be responsible for the pre/ clinical development of HLX04, whereas Essex is responsible for regulatory …

Henlius Signs a License Agreement with Essex to Co-develop HLX04 (biosimilar, bevacizumab) for Ophthalmic Diseases Read More »

Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B

Shots: Dyno to receive upfront and is eligible to receive ~$1.8B milestones including development and commercial milestones along with royalties on any product emerges during the collaboration Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy while Roche and Spark will conduct preclinical, clinical, and commercialization …

Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B Read More »

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease

Shots: Arrowhead to receive ~$300M up front, ~$740M as development, regulatory and commercial milestones and is eligible to receive royalties of 20-25% on net sales If approved, the companies will co-develop ARO-AAT and co-commercialize it in the US, under 50/50 profit sharing structure. Additionally, Takeda will lead the global commercialization strategy and get an exclusive …

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease Read More »

Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung Diseases

Shots: The agreement leverages Imbio’s technical, regulatory & commercial expertise to build medical imaging AI technology for use in research, clinical trials & clinical practice The focus of the agreement is to develop quantitative imaging diagnostics for lung diseases and to bring unique solutions for pulmonary imaging. The collaboration integrates Imbio’s expertise in imaging biomarkers …

Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung Diseases Read More »

AbbVie and Harvard University Collaborate to Develop Novel Therapies Against Emergent Viral Diseases

Shots: AbbVie and Harvard University enter a $30M research alliance to study & develop novel therapies against emergent viral infections with an initial focus on coronavirus and the viruses leading to hemorrhagic fever The focus of the collaboration is to integrate fundamental biology into the pre/clinical development of new therapies for viral diseases AbbVie will …

AbbVie and Harvard University Collaborate to Develop Novel Therapies Against Emergent Viral Diseases Read More »

Bayer and One Drop Collaborate to Develop Digital Therapies Across Multiple Therapeutic Areas

Shots: The two partners will jointly enhance the existing platform utilizing One Drop’s know-how and capabilities of the One Drop platform and will co-develop digital health therapies across multiple therapeutic areas                One Drop will receive $98M financing, development fees and commercial milestones while in exchange Bayer will receive royalties on sales. In the future, Bayer …

Bayer and One Drop Collaborate to Develop Digital Therapies Across Multiple Therapeutic Areas Read More »

AstraZeneca Collaborates with RenalytixAI to Develop Precision Medicine for Chronic Diseases

Shots: The two companies will develop and launch precision medicine strategies for CV, renal, and metabolic diseases. The first stage in the collaboration will use KidneyIntelX to improve outcomes for patients with CKD and its complications, in coordination with the Mount Sinai Health System The first stage will assess the impact of AI-enabled in vitro …

AstraZeneca Collaborates with RenalytixAI to Develop Precision Medicine for Chronic Diseases Read More »

Solasia Signs a License Agreement with Isofol to Develop and Commercialize Arfolitixorin for mCRC in Japan

Shots: Isofol to receive $100M as up front, development, regulatory and commercial milestones, and clinical development cost and is eligible to receive royalties on sales of the therapy and retain its right to the therapy in ROW Solasia will lead clinical development activities in Japan and will be responsible for registrational filing and approval in …

Solasia Signs a License Agreement with Isofol to Develop and Commercialize Arfolitixorin for mCRC in Japan Read More »

Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH

Shots: Hanmi to receive $10M up front, $860M as development, regulatory approval, and commercialization of efinopegdutide along with royalties on sales of the approved product Merck to receive an exclusive license to develop, manufacture and commercialize efinopegdutide in the US and globally while Hanmi to retain an option to commercialize the therapy in Korea Efinopegdutide …

Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH Read More »

Sangamo Signs a Worldwide License Agreement with Novartis to Develop Genomic Therapies for Three Neurodevelopmental Targets

Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales of the product. Additionally, Sangamo to take care of certain research and manufacturing activities funded by Novartis Novartis to get exclusive license rights of ZFP-TFs …

Sangamo Signs a Worldwide License Agreement with Novartis to Develop Genomic Therapies for Three Neurodevelopmental Targets Read More »

Roche and UCB Collaborate to Develop UCB0107 for Alzheimer’s Disease

Shots: UCB to receive $120M and is eligible to receive $2B as cost reimbursement, development, and commercial milestones as well as royalties on sales of the therapies, if Roche proceeds the clinical development. Roche to get an exclusive license to develop and commercialize UCB0107 for AD UCB to fund and perform a POC study in …

Roche and UCB Collaborate to Develop UCB0107 for Alzheimer’s Disease Read More »

AstraZeneca Signs an Agreement with Daichii Sankyo to Develop and Commercialize DS-1062 Worth Up to $6B

Shots: Daichii Sankyo to receive $1B as upfront of which $350M is due upon execution, $325M after 12mos. and $325M after 24 mos., ~$5B as contingent payment including $1B as regulatory milestones, and $4B as commercial milestones, making a total deal value up to ~6B The companies will jointly develop and commercialize DS-1062 globally and …

AstraZeneca Signs an Agreement with Daichii Sankyo to Develop and Commercialize DS-1062 Worth Up to $6B Read More »

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer

Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical studies with an IND submission targeted for Aug’2020. The transaction is expected to be close in Aug’2020. The integration of Sorrento’s G-MAB Ab library and SmartPharm’s GET platform is expected …

Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer Read More »

Chugai and Biofourmis Collaborate to Develop Solutions for Digitally Measuring Endometriosis Pain

Shots: The collaboration will deploy Biofourmis’ Biovitals platform to co-develop a novel digital technology for the objective assessment of pain using biosensors and AI-based algorithms. The solutions will be validated in the global study that enrolls 120+ endometriosis patients The digital solution for managing patients with endometriosis in an ambulatory setting will include a wearable, …

Chugai and Biofourmis Collaborate to Develop Solutions for Digitally Measuring Endometriosis Pain Read More »

Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases

Shots: The two companies collaborated to discover and develop novel therapeutics interfering with the disease-causing transcriptional programs in cancer and other diseases. Quantro intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts Quantro will exploit its functional-genetic and transcriptomic technologies addressing the undruggable targets while Evotec will …

Evotec Collaborates with Quantro Therapeutics to Discover and Develop Novel Therapies for Cancer and Other Diseases Read More »

GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

Shots: GenScript will be responsible for all pre-clinical pharmacy research and IND filling in Selecxine’s project which is based on cytokine-antibody complexes The company provided development solutions in different hosts tailored to customers and provided the preparation and purification solutions for the final complex,; further the project will test and enhance the process development capability …

GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology Read More »